IVA
NASD Inventiva SA ADR$3.16 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.16, $0.19 below the day’s high of $3.35
- YTD change
- -32.04%
- vs 20-day SMA
- -11.75%
- vs 200-day SMA
- -36.84%
Price ranges
Price & Performance
-1.85 (-36.93%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 83.4% away from all-time highs of $19.06
- IVA is down 32% since the beginning of the year
- IVA is down 43% over the past 12 months
- IVA is down 24% over the past 1 month
- 3% of all IVA investors are betting against IVA
IVA reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -31.5%.
- Previous minute
- +$0.00
- Last hour
- -$0.10
- Last 5 days
- -8.67%
- vs 8-day SMA
- -8.49%
No alerts for IVA in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
